Neovascular (wet) Age Related Macular Degeneration Therapeutics

1. Macugen patent expiration

Treatment: Treatment of vegf mediated ocular disease.

MACUGEN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6051698 BAUSCH AND LOMB INC Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
May, 2015

(10 years ago)

US6113906 BAUSCH AND LOMB INC Water-soluble non-antigenic polymer linkable to biologically active material
Oct, 2013

(12 years ago)

US5919455 BAUSCH AND LOMB INC Non-antigenic branched polymer conjugates
Oct, 2013

(12 years ago)

US6011020 BAUSCH AND LOMB INC Nucleic acid ligand complexes
Jan, 2017

(9 years ago)

US5932462 BAUSCH AND LOMB INC Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
Aug, 2016

(9 years ago)




Drugs and Companies using PEGAPTANIB SODIUM ingredient

Market Authorisation Date: 17 December, 2004

Dosage: INJECTABLE

More Information on Dosage

MACUGEN family patents

Family Patents

2. Visudyne patent expiration

Treatment: Use of the drug product in photodynamic therapeutic protocols for the treatment of age-related macular degeneration and related conditions involving unwanted neovasculature in the eye

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5756541 BAUSCH LOMB IRELAND Vision through photodynamic therapy of the eye
Mar, 2016

(9 years ago)

US5770619 BAUSCH LOMB IRELAND Method of activating photosensitive agents
Jan, 2015

(11 years ago)

US5798349 BAUSCH LOMB IRELAND Use of green porphyrins to treat neovasculature in the eye
Aug, 2015

(10 years ago)

US5707608 BAUSCH LOMB IRELAND Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
Aug, 2015

(10 years ago)




Drugs and Companies using VERTEPORFIN ingredient

Market Authorisation Date: 12 April, 2000

Dosage: INJECTABLE

More Information on Dosage

VISUDYNE family patents

Family Patents